Genflow Biosciences SIRT6 AAV (GF-1002) — Gene Therapy & Genetic Interventions
AAV-delivered SIRT6 gene therapy developed by Genflow Biosciences for age-related diseases.
Overview
Genflow Biosciences is a Belgian biotech company developing SIRT6-based gene therapies for age-related diseases. Their lead program GF-1002 uses AAV vectors to deliver a centSIRT6 variant (derived from long-lived Bowhead whale SIRT6, which has 5x greater DNA repair activity than human SIRT6). Preclinical data demonstrates improved DNA repair, reduced inflammation, and reversal of age-related metabolic changes. Genflow's approach targets specific age-related indications rather than aging broadly, with Progeria (Hutchinson-Gilford Progeria Syndrome) as their initial indication to facilitate regulatory approval.
Indications
- Hutchinson-Gilford Progeria Syndrome (lead indication)
- Age-related metabolic disease
- Genomic instability syndromes
- Werner syndrome
- Broader age-related disease (long-term pipeline)
Mechanism of Action
AAV vector delivers enhanced Bowhead whale-derived SIRT6 gene to target cells
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| GF-1002 (AAV-centSIRT6) | Study-specific | Single infusion | IND-enabling studies; Bowhead whale SIRT6 variant |
Evidence Grade
GRADE D
Safety & Contraindications
- Bowhead whale-derived SIRT6 variant may trigger immune responses in humans
- AAV vector safety profile well-characterized from other gene therapy programs
- High-dose AAV hepatotoxicity is a class-wide concern
- Preclinical safety data reported as favorable by the company
- Progeria patients represent a high-unmet-need population with risk tolerance
- No human clinical trial data available